ENA 78 Human (8-78 a.a.)
(a) Analysis by RP-HPLC.
(b) Analysis by SDS-PAGE.
Description
Epithelial Neutrophil-Activating Protein 78 Human Recombinant produced in E.Coli is a single, non-glycosylated, polypeptide chain containing 71 amino acids (8-78 a.a.) and having a molecular mass of 7.8kDa. The CXCL5 is purified by proprietary chromatographic techniques.
Product Specs
Recombinant Human Epithelial Neutrophil-Activating Protein 78, produced in E. coli, is a single, non-glycosylated polypeptide chain consisting of 71 amino acids (8-78 a.a.). This protein has a molecular weight of 7.8 kDa. The CXCL5 is purified using proprietary chromatographic techniques.
(a) Reverse-Phase High-Performance Liquid Chromatography (RP-HPLC) analysis.
(b) SDS-PAGE analysis.
Product Science Overview
CXCL5 is produced by various cell types, including epithelial cells, in response to inflammatory cytokines such as interleukin-1 (IL-1) and tumor necrosis factor-alpha (TNF-α) . The protein consists of 78 amino acids and has a molecular weight of approximately 8.3 kDa . The recombinant form of CXCL5, specifically the 8-78 amino acid sequence, is often used in research to study its biological functions and therapeutic potential.
CXCL5 is primarily involved in the recruitment and activation of neutrophils, a type of white blood cell essential for the immune response. Upon binding to its receptor, CXCR2, on the surface of neutrophils, CXCL5 induces chemotaxis, guiding these cells to the site of infection or injury . This process is vital for the body’s defense against pathogens and the resolution of inflammation.
Research has shown that CXCL5 plays a significant role in various inflammatory diseases and conditions. For instance, elevated levels of CXCL5 have been observed in patients with acute coronary syndromes (ACS), suggesting its involvement in endothelial inflammation . Additionally, studies have indicated that genetic variations in the CXCL5 gene may influence the prognosis of ACS and the effectiveness of statin therapy .
Given its role in inflammation and immune response, CXCL5 is a potential target for therapeutic interventions. Modulating the activity of CXCL5 or its receptor, CXCR2, could provide new treatment options for inflammatory diseases, including cardiovascular diseases and chronic inflammatory conditions .
